DK1343525T3 - Forbedret Mycoplasma hyopneumonia bacterinvaccine - Google Patents

Forbedret Mycoplasma hyopneumonia bacterinvaccine

Info

Publication number
DK1343525T3
DK1343525T3 DK01990123T DK01990123T DK1343525T3 DK 1343525 T3 DK1343525 T3 DK 1343525T3 DK 01990123 T DK01990123 T DK 01990123T DK 01990123 T DK01990123 T DK 01990123T DK 1343525 T3 DK1343525 T3 DK 1343525T3
Authority
DK
Denmark
Prior art keywords
enhanced
bacterin vaccine
mycoplasma hyopneumonia
hyopneumonia
mycoplasma
Prior art date
Application number
DK01990123T
Other languages
Danish (da)
English (en)
Inventor
Hsien-Jue Steve Chu
Wumin Li
Zhichang Xu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22972978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1343525(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1343525T3 publication Critical patent/DK1343525T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK01990123T 2000-12-19 2001-12-11 Forbedret Mycoplasma hyopneumonia bacterinvaccine DK1343525T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25663700P 2000-12-19 2000-12-19
PCT/US2001/047865 WO2002049666A2 (en) 2000-12-19 2001-12-11 Mycoplasma hyopneumoniae bacterin vaccine

Publications (1)

Publication Number Publication Date
DK1343525T3 true DK1343525T3 (da) 2007-06-04

Family

ID=22972978

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01990123T DK1343525T3 (da) 2000-12-19 2001-12-11 Forbedret Mycoplasma hyopneumonia bacterinvaccine

Country Status (28)

Country Link
US (4) US20020131980A1 (ko)
EP (1) EP1343525B1 (ko)
JP (2) JP5074656B2 (ko)
KR (1) KR100874119B1 (ko)
CN (1) CN1296095C (ko)
AR (1) AR033410A1 (ko)
AT (1) ATE359813T1 (ko)
AU (2) AU2899302A (ko)
BG (1) BG66213B1 (ko)
BR (1) BRPI0116249B1 (ko)
CY (1) CY1106669T1 (ko)
CZ (1) CZ307075B6 (ko)
DE (1) DE60127994T2 (ko)
DK (1) DK1343525T3 (ko)
ES (1) ES2283452T3 (ko)
HK (1) HK1056513A1 (ko)
HR (1) HRP20030585B1 (ko)
HU (1) HU227431B1 (ko)
ME (1) ME00570A (ko)
MX (1) MXPA03005357A (ko)
MY (1) MY129765A (ko)
NZ (1) NZ526904A (ko)
PL (1) PL211174B1 (ko)
PT (1) PT1343525E (ko)
RS (1) RS51536B (ko)
TW (1) TWI308872B (ko)
WO (1) WO2002049666A2 (ko)
ZA (1) ZA200305545B (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
GB0400264D0 (en) * 2004-01-07 2004-02-11 Polytherics Ltd Complexes
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
EP2371385B1 (en) 2005-12-29 2015-08-19 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
BR122015028489B1 (pt) 2005-12-29 2021-10-13 Boehringer Ingelheim Animal Health Usa Inc Vacina de combinação multivalente contra pcv2, bem como uso de uma proteína orf2 na preparação da mesma
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
CA2670836C (en) 2006-12-15 2018-09-04 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with pcv2 antigen
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
AU2008324780A1 (en) 2007-11-06 2009-05-14 Pah W Llc Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
MX2010007815A (es) 2008-01-23 2010-08-10 Boehringer Ingelheim Vetmed Composiciones inmunogenicas de mycoplasma hyopneumoniae contra pcv2 y metodos para producir composiciones de este tipo.
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
MX2010014078A (es) * 2008-06-25 2011-04-11 Braasch Biotech Llc Composiciones y metodos para inmunogenecidad mejorada de somatostatina.
AU2010251761B2 (en) * 2009-05-19 2014-10-09 Bioproperties Pty Ltd A temperature sensitive vaccine strain of Mycoplasma hyopneumoniae and uses thereof
CA2764424C (en) 2009-06-04 2019-12-31 National Institute Of Advanced Industrial Science And Technology Vaccine for mycoplasma infection
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CN102573900B (zh) * 2009-09-10 2017-05-31 梅里亚股份有限公司 包含含有皂苷的佐剂的新疫苗制剂
EP2563389B1 (en) 2010-04-30 2015-07-08 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
WO2013149017A1 (en) * 2012-03-28 2013-10-03 Kansas State University Research Foundation Vaccine adjuvant
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
CN103623400B (zh) * 2012-08-24 2016-08-17 普莱柯生物工程股份有限公司 抗猪支原体肺炎、传染性胸膜肺炎疫苗组合物及制备方法
CN104981252B (zh) 2012-12-28 2019-06-18 勃林格殷格翰动物保健有限公司 包含支原体抗原的免疫原性组合物
SG10201708028VA (en) 2012-12-28 2017-10-30 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
CN104338128B (zh) * 2013-07-31 2017-09-05 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
EA035265B1 (ru) 2013-10-02 2020-05-21 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
CA3082959A1 (en) * 2017-12-04 2019-06-13 Intervet International B.V. Canine lyme disease vaccine
CN108324941A (zh) * 2018-04-03 2018-07-27 林淑卿 猪疾病疫苗用佐剂及其制备方法
CN117100851A (zh) * 2023-10-23 2023-11-24 成都依思康生物科技有限公司 一种佐剂、疫苗组合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3790665A (en) 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1267087A (en) 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
EP0283085B1 (en) 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
EP0513861B1 (en) * 1987-11-03 1997-02-26 Syntex (U.S.A.) Inc. Vaccine adjuvant comprising a tetra-polyol
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
DE69128361T3 (de) 1990-05-29 2006-04-13 Wyeth Holdings Corp. Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5695769A (en) * 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
AU667858B2 (en) 1991-11-15 1996-04-18 Smithkline Beecham Corporation Gram-negative bacterial vaccines
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) * 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
JP3265095B2 (ja) * 1993-11-19 2002-03-11 本田技研工業株式会社 キャニスタ
SI0759780T1 (en) * 1994-05-10 2000-12-31 American Home Products Corporation Improved modified live brsv vaccine
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
JP2001515467A (ja) * 1996-12-20 2001-09-18 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム モラクセラ・カタラーリスのｕｓｐａ１及びｕｓｐａ２抗原
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6342231B1 (en) * 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
KR20040030785A (ko) * 2001-07-02 2004-04-09 화이자 프로덕츠 인크. 마이코플라즈마 하이오뉴모니애로의 1회 투여량 예방접종
US20050220880A1 (en) * 2002-03-07 2005-10-06 Lewis Andrew L Drug carriers comprising amphiphilic block copolymers
ITMI20030269A1 (it) * 2003-02-14 2004-08-15 Advance Holdings Ltd Sale di cetilpiridino di un agente antiinfiammatorio
US8052762B1 (en) * 2010-09-02 2011-11-08 Kelly Van Gogh, LLC Compositions for dyeing keratin-containing fibers

Also Published As

Publication number Publication date
KR100874119B1 (ko) 2008-12-15
US7666439B2 (en) 2010-02-23
PL211174B1 (pl) 2012-04-30
DE60127994T2 (de) 2008-01-17
KR20030065556A (ko) 2003-08-06
US20100119471A1 (en) 2010-05-13
PL363220A1 (en) 2004-11-15
EP1343525B1 (en) 2007-04-18
BR0116249A (pt) 2004-03-02
CN1296095C (zh) 2007-01-24
HRP20030585B1 (en) 2008-03-31
AU2899302A (en) 2002-07-01
ZA200305545B (en) 2004-10-18
HUP0400687A2 (hu) 2004-06-28
BRPI0116249B1 (pt) 2016-06-14
ATE359813T1 (de) 2007-05-15
PT1343525E (pt) 2007-07-12
US20120213816A1 (en) 2012-08-23
ME00570B (me) 2011-12-20
CN1489472A (zh) 2004-04-14
WO2002049666A3 (en) 2003-02-06
CY1106669T1 (el) 2012-05-23
ES2283452T3 (es) 2007-11-01
MY129765A (en) 2007-04-30
US20020131980A1 (en) 2002-09-19
HRP20030585A2 (en) 2005-06-30
EP1343525A2 (en) 2003-09-17
JP2004518655A (ja) 2004-06-24
DE60127994D1 (de) 2007-05-31
BG107898A (bg) 2004-08-31
NZ526904A (en) 2005-07-29
TWI308872B (en) 2009-04-21
US8187588B2 (en) 2012-05-29
US9238065B2 (en) 2016-01-19
MXPA03005357A (es) 2003-10-06
CZ20031721A3 (cs) 2004-04-14
HUP0400687A3 (en) 2004-10-28
JP5074656B2 (ja) 2012-11-14
YU49303A (sh) 2006-08-17
WO2002049666A2 (en) 2002-06-27
AU2002228993B2 (en) 2006-06-29
CZ307075B6 (cs) 2018-01-03
BG66213B1 (bg) 2012-05-31
RS51536B (sr) 2011-06-30
JP2009073855A (ja) 2009-04-09
US20070020296A1 (en) 2007-01-25
HU227431B1 (en) 2011-06-28
ME00570A (en) 2011-12-20
AR033410A1 (es) 2003-12-17
HK1056513A1 (en) 2004-02-20

Similar Documents

Publication Publication Date Title
DK1343525T3 (da) Forbedret Mycoplasma hyopneumonia bacterinvaccine
NO20031483D0 (no) Vaksine
NO20024172D0 (no) Vaksine
ATE534402T1 (de) Multivalente impfstoffzusammensetzung
NO20034683D0 (no) Intradermal vaksineinnretning
NO20030823D0 (no) Vaksiner
DK1946772T3 (da) Multivalent vaccinesammensætning
NO20031705D0 (no) Vaksiner
NO20035762L (no) En-dose vaksinering med mykoplasma hyopneumoniae
FR14C0016I2 (fr) Vacccin west nile
AU2002228993A1 (en) Mycoplasma hyopneumoniae bacterin vaccine
ATE346608T1 (de) Impstoff gegen streptococcus pneumoniae
NO20043018L (no) Streptococcus pneumoniae vaksine
DK1265633T3 (da) Vaccineadjuvans
DK1267899T3 (da) ssa-inaktiverede salmonellavacciner
DE10293048T1 (de) Neuer Impfstoff
NO20033882L (no) Vaksine
NO20030423D0 (no) Temperatursensitiv levende vaksine mot Mycoplasma hyopneumoniae
AU2002335609A8 (en) Multivalent mycoplasma bacterin
NO20005599D0 (no) Vaksine
NO20032086D0 (no) Adjuvant kombinasjonsformuleringer
IT1314647B1 (it) Dispositivo antinebbia
SE0003296D0 (sv) Krökbar anordning